204 related articles for article (PubMed ID: 18954562)
1. 4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo.
Li Q; Ai J; Song Z; Liu J; Shan B
Cell Mol Immunol; 2008 Oct; 5(5):379-84. PubMed ID: 18954562
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses.
Kuang Y; Weng X; Liu X; Zhu H; Chen Z; Jiang B; Chen H
Cancer Lett; 2010 Jul; 293(2):254-62. PubMed ID: 20149524
[TBL] [Abstract][Full Text] [Related]
3. [Prostate cancer cell vaccine transfected with 4-1BBL induces anti-tumor immunity in vitro].
Kuang YL; Weng XD; Liu XH; Chen ZY; Zhu HC; Jiang BT
Zhonghua Nan Ke Xue; 2010 Sep; 16(9):773-7. PubMed ID: 21171257
[TBL] [Abstract][Full Text] [Related]
4. Extracellular domain of human 4-1BBL enhanced the function of cytotoxic T-lymphocyte induced by dendritic cell.
Wu C; Guo H; Wang Y; Gao Y; Zhu Z; Du Z
Cell Immunol; 2011; 271(1):118-23. PubMed ID: 21745658
[TBL] [Abstract][Full Text] [Related]
5. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
6. [Antitumor immune responses induced by gene transfer of 4-1BBL into hepatocellular carcinoma Hepa1-6 in vitro].
Liu CL; Dou KF; Zang XX; Zhu BF; Chen SM
Zhonghua Wai Ke Za Zhi; 2004 May; 42(9):554-8. PubMed ID: 15196371
[TBL] [Abstract][Full Text] [Related]
7. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
8. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.
DeBenedette MA; Wen T; Bachmann MF; Ohashi PS; Barber BH; Stocking KL; Peschon JJ; Watts TH
J Immunol; 1999 Nov; 163(9):4833-41. PubMed ID: 10528184
[TBL] [Abstract][Full Text] [Related]
9. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.
Guinn BA; Bertram EM; DeBenedette MA; Berinstein NL; Watts TH
Cell Immunol; 2001 May; 210(1):56-65. PubMed ID: 11485353
[TBL] [Abstract][Full Text] [Related]
10. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.
Lu ZY; Condomines M; Tarte K; Nadal L; Delteil MC; Rossi JF; Ferrand C; Klein B
Exp Hematol; 2007 Mar; 35(3):443-53. PubMed ID: 17309825
[TBL] [Abstract][Full Text] [Related]
11. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
Müller D; Frey K; Kontermann RE
J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
[TBL] [Abstract][Full Text] [Related]
12. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
[TBL] [Abstract][Full Text] [Related]
13. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo.
Yan X; Johnson BD; Orentas RJ
Immunology; 2004 May; 112(1):105-16. PubMed ID: 15096190
[TBL] [Abstract][Full Text] [Related]
14. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.
Wang C; Lin GH; McPherson AJ; Watts TH
Immunol Rev; 2009 May; 229(1):192-215. PubMed ID: 19426223
[TBL] [Abstract][Full Text] [Related]
15. [Cloning, expression and antitumor effect of mouse costimulatory molecule 4-1BBL].
Liu CL; Dou KF; Zhu BF; Zang XX; Chai YB; Du KJ; Chen SM
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Jan; 20(1):118-22. PubMed ID: 15182637
[TBL] [Abstract][Full Text] [Related]
16. Anti-prostate cancer effects of CTL cell induction in vitro by recombinant adenovirus mediated PSMA/4-1BBL dendritic cells: an immunotherapy study.
Sui CG; Wu D; Meng FD; Yang MH; Jiang YH
Genet Mol Res; 2015 Jun; 14(2):7208-17. PubMed ID: 26125931
[TBL] [Abstract][Full Text] [Related]
17. Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
Cheuk AT; Mufti GJ; Guinn BA
Cancer Gene Ther; 2004 Mar; 11(3):215-26. PubMed ID: 14671675
[TBL] [Abstract][Full Text] [Related]
18. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB ligand signaling to T cells limits T cell activation.
Eun SY; Lee SW; Xu Y; Croft M
J Immunol; 2015 Jan; 194(1):134-41. PubMed ID: 25404362
[TBL] [Abstract][Full Text] [Related]
20. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
Wen T; Bukczynski J; Watts TH
J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
